This retrospective study evaluated clinical outcomes in 124 consecutive gastroesophageal reflux disease (GERD) patients who underwent transoral incisionless fundoplication (TIF) at 2 community hospitals. Out of 123 patients treated successfully, 110 gave consent (74% female, median age 60 [range 21-87] years, body mass index 27.5 [19.0-47.9]). At a median 7-month follow-up (range 5-17), typical and atypical symptom scores were normalized in 75% to 80% of patients, proton pump inhibitors (PPIs) were completely discontinued by 93%, and 83% were satisfied with their current health condition. Endoscopy in 53 patients revealed Hill grade I tight valves in 89% of the cases, reduced hiatal hernia in 33/34 (97%), and healed reflux esophagitis in 25/30 (83%). Based on global analysis, 72% of the patients were in remission, 20% improved symptomatically, and only 8% had ongoing GERD. These results supported the safety and efficacy of TIF as well as encouraged its application as an alternative treatment of GERD refractory to PPIs.
Introduction
Gastroesophageal reflux disease (GERD) is one of the most frequent disorders seen in primary care and community practice settings in the United States. 1 Although GERD is not a life-threatening disease, it can cause serious complications such as esophageal stricture, Barrett's esophagus, or adenocarcinoma. 2 Given the spectrum and chronic nature of the disease, GERD has a greater negative impact on patients' quality of life than diabetes, hypertension, myocardial infarction, or arthrithis. 3 It has also been associated with substantial direct and indirect health care costs and has a significant economic impact on both employers and employees. 4 These negative health and economic effects highlight the importance of managing the disease effectively. 4, 5 Proton pump inhibitors (PPIs) dominate prescribing practices as a frontline treatment for acid reflux. 6 However, medical therapy does not cure the disease, and failure to respond to standard dose of PPIs is very common. According to recent reports, 25% to 40% of GERD patients with heartburn and regurgitation and 30% to 50% of those with atypical symptoms do not respond symptomatically to a standard dose of PPIs. [7] [8] [9] The lack of symptom control results in patient dissatisfaction and quality-of-life deterioration. [10] [11] [12] The current standard of care offers limited treatment options for patients with inadequately controlled symptoms despite high doses of PPIs. 13, 14 Antireflux surgery using laparoscopic Nissen technique is effective in preventing both acid and nonacid reflux in patients with both typical and atypical GERD symptoms. 15, 16 However, this technique creates supercompetent gastroesophageal valves that often lead to new iatrogenic side effects such as bloating and dysphagia. [17] [18] [19] [20] Furthermore, laparoscopic Nissen fundoplication has been shown to have poorer results in community practice than in expert centers with large volume recruitment. 21 The high prevalence of postoperative complications, poorer outcomes, and somatic anxiety 22 makes community patients very reluctant to consider surgery. Both the patients who suffer from GERD and the physicians who treat them look for an alternative.
Transoral incisionless fundoplication (TIF) using EsophyX offers a less invasive alternative to laparoscopic fundoplication for patients with moderate anatomic defects in the gastroesophageal junction. Patients with a hiatal hernia can be candidates for TIF if the axial height and transverse dimensions do not exceed 3 cm. 23 It has been used in more than 4000 patients worldwide and is gaining popularity because of its high safety profile, good clinical outcomes, and minimal invasiveness. European studies with the early gastro-gastric TIF1 procedure in small series reported reasonable results in treating chronic GERD patients responsive to PPIs. [24] [25] [26] [27] [28] A more recent case study in the United States with esophago-gastric TIF2 showed significantly improved subjective and objective outcomes in more than 70% of the patients with GERD symptoms resistant to PPIs. 29 The purpose of this retrospective study was to evaluate clinical outcome in terms of symptoms, patient satisfaction, medication use, and resolution of reflux-related complications in GERD patients who underwent TIF2 at 2 community hospitals because they had persistent symptoms on high-dose PPI therapy, proven gastroesophageal reflux, and moderate deterioration of the gastroesophageal junction anatomy.
Patients and Methods
A total of 124 consecutive patients underwent TIF between November 2008 and December 2009 at 2 community hospitals: n = 64 at the Livingston Hospital and Healthcare Services (LHHS), a critical access hospital in rural Kentucky, and n = 60 at the Munroe Regional Medical Center (MRMC), a large community hospital in Florida. Patients underwent TIF because they had chronic symptomatic GERD, persistent symptoms on daily PPI therapy, documented gastroesophageal reflux by repeated endoscopy or barium swallow, and deteriorated gastroesophageal junction. Several patients opted for TIF because they were afraid of complications after laparoscopic Nissen, had limited surgical options due to a previous surgery, or preferred TIF because of its minimal invasiveness and faster return to work. 24, 28, 29 At LHHS, suitable patients were referred for TIF by WB during a regular check-up. At MRMC, the majority of TIF patients had attended patient seminars organized by the hospital.
The preoperative evaluation of TIF patients followed our routine protocols for Nissen patients and comprised complete history and physical, symptom evaluation, and endoscopy. These patients presented with a chief complaint of gastroesophageal reflux or reflux-associated symptoms. An extensive history and physical examination was taken in a standard fashion to confirm that the complaint and the illness correlated. If the symptoms and the physical examination did not confirm the diagnosis of reflux these patients were worked up to find out the cause of their symptoms. All patients underwent gastroesophagoduodonoscopy (EGD), most often with biopsy (all patients at LHHS and those with visible inflammation at MRMC), to evaluate the condition of their esophageal and gastric mucosa and the gastroesophageal junction geometry. Certain patients with a hiatal hernia underwent a barium swallow test. Patients were recommended for TIF if they had reflux-associated complications or confirmed reflux by EGD or barium swallow. At both institutions pH and motility studies were not available and so were not used.
According to the manufacturer's instructions for use, EsophyX is contraindicated for patients with bleeding disorders, strictures, severe esophagitis, esophageal diverticulae, obstructions, paraesophageal hernia, limited neck mobility, osteophytes of the spine, esophageal varices, esophageal infections or fungal disease, esophageal stenosis, and any kind of normal or abnormal anatomy that would not permit safe insertion of a device of this same size, chronic cough, body mass index (BMI) >35, or hiatal hernia of >2 cm.
In our series, patients with BMI >35 were considered for TIF if they were not willing to undergo or were at high risk of complications from laparoscopic surgery. Patients with hiatal hernia of 3 cm in axial length were considered for TIF if the hiatal hernia was reducible and had the transverse dimension not exceeding 3 cm. 23 All procedures were performed using the EsophyX2 device (EndoGastric Solutions, Inc, Redmond, WA) and followed the standardized TIF2 technique previously described in detail by Bell and Cadiere 23 and summarized below.
After completing TIF training and satisfying credential requirements, each of us performed TIF procedures independently at either an endoscopy suite (LHHS) or operating room (MRMC). Patients were placed in a left lateral decubitus position, except obese patients who were positioned in a reverse Trendelenburg position to lessen pressure on the gastroesophageal junction from the liver. The procedure was performed under general endotracheal anesthesia. The location of the diaphragmatic hiatus and its dimensions were determined during preoperative endoscopy. 23 Esophageal dilation was performed on all LHHS patients with 56 to 60 Fr Maloney for 5 minutes to facilitate device insertion. The EsophyX device was introduced over a flexible endoscope into the stomach. With the endoscope retroflexed for visualization, the device's tissue mold was retroflexed. Carbon dioxide insufflation was used intraoperatively at both sites. From the apex of the device a helical retractor was advanced into the Z-line at the lesser curvature of the stomach. The exact edge of the diaphragm was located through a palpitation technique. With caudal retraction on the helical retractor, the tissue mold was used to rotate the fundus up and around the esophagus. The tissue mold and helix were locked in place, and polypropylene H-shaped fasteners were placed between the esophageal lumen and the gastric cardia up to 5 cm above the Z-line ( Figure 1 ). This procedure was repeated at several rotational positions and longitudinal depths until 12 to 20 fasteners were deployed. At MRMC an additional 6 to 10 fasteners were deployed to fortify the wrap. This resulted in an esophago-gastric plication that extended above the Z-line for 3 to 5 cm and circumferentially for more than 270° as visualized endoscopically.
Postoperative stay was 1 day in all cases. Patients routinely received preoperatively and postoperatively a combination of intravenous pain medication, antibiotics, antiemetics, and anticholinergics. Anticoagulants, if used, were discontinued for 7 days before TIF and resumed the day after TIF. PPI therapy was continued postoperatively for 2 weeks to reduce the risk of gastric bleeding. Patients at LHHS were informed about natural acid rebound during the first 3 months after stopping PPIs 30 and were advised to take Tums as needed.
Patients followed a postoperative diet during the first 6 weeks after TIF that consisted of liquids for 2 weeks, soft/pureed foods for 2 more weeks, and normal diet without meat and fibrous vegetables for the last 2 weeks. Patients were given instructions to walk after surgery, avoid lifting anything heavier than 5 pounds during the first 3 to 5 weeks, and not to engage in vigorous sports or other physical activities for the first 6 weeks. Patients could resume driving and return to work within 3 to 5 days after surgery.
All patients were seen at either week 1 (LHHS) or week 2 (MRMC) and then at 1 and 3 months at both institutions and every 6 months postoperatively at LHHS. Patients were asked to contact their physician in case symptoms returned. At LHHS patients were seen more often as they were followed for other conditions by the same physician (WB).
After obtaining an approval from the LHHS's Institutional Review Board, 60 of the 64 (94%) treated patients agreed to consent to a retrospective evaluation of their clinical course and came for a follow-up visit to complete questionnaires and answer questions regarding their medication use. At MRMC, questionnaires and volunteer consent forms were sent to all 60 patients by mail and returned completed by 50 (83%).
Demographic and clinical data were collected from patient charts for 110 patients. Follow-up assessment was conducted at 6 or 12 months and evaluated typical and atypical symptoms using 3 GERD-specific questionnaires: GERD-HRQL (GERD Health-Related Quality of Life), GERSS (GERD Symptom Score), and RSI (Reflux Symptom Index). At follow-up patients were also asked to complete the same 3 questionnaires on their symptoms before TIF based on recall. The primary clinical effectiveness measure was symptom elimination at the follow-up based on score normalization. Typical symptoms were evaluated using GERD-HRQL and GERSS questionnaires. The GERD-HRQL is a validated disease-specific questionnaire measuring 10 items (6 related to heartburn) on a scale from 0 (no symptoms) to 5 (worst symptoms), with highest total score of 50. 31, 32 Scores were considered normalized if every score equaled 0. Patient satisfaction with their current health condition was assessed as "satisfied," "neutral," or "dissatisfied" based on answers to GERD-HRQL question 11. The GERSS questionnaire was developed and validated to measure both typical and atypical symptoms associated with GERD-namely, heartburn, regurgitation, abdominal distention, dysphagia, and cough. 33, 34 Each of the 5 symptoms was scored as a product of severity (0 "not at all" to 3 "severely") and frequency (0 "never" to 4 "daily"). Item scores varied from 0 to 12, and the total scores from 0 to 60. Patients with controlled reflux symptoms with either medical or surgical therapy are expected to have a total symptom score of less than 18. 34 Atypical symptoms were evaluated using RSI scores. The RSI is a 9-item questionnaire that was developed and validated to measure symptoms associated with laryngopharyngeal reflux (LPR) such as hoarseness, throat clearing, excess throat mucus, dysphagia, and cough. 35 The scale for each individual item ranges from 0 ("no problem") to 5 ("severe problem"), with a maximum total score of 45 and a normality threshold at ≤13.
Secondary clinical effectiveness measures were a complete PPI discontinuation, hiatal hernia reduction, healing of esophagitis, and normalization of the gastroesopheal junction's geometry. The use of PPIs and other GERD medications such as histamine receptor antagonists (H2RA) and antacids was recorded and categorized as "daily," "occasional," or "none." A complete discontinuation of PPIs was considered clinically significant.
A complete EGD examination with biopsy was performed to assess the quality and durability of TIF repair, as well as the status of hiatal hernia reduction and healing of esophagitis and other reflux-related complications, if present preoperatively. Hiatal hernia size was defined as a distance from the Z-line to the diaphragmatic pinch measured in centimeters at retraction of the endoscope without insufflation. Reflux esophagitis was graded according to the Los Angeles Classification, 36 and the geometric aspects of the TIF valves such as length, circumference, adherence to the endoscope, and Hill grade were determined. 37, 38 Reduction of hiatal hernia to <1 cm, completely healed esophagitis, and Hill grade I were considered as successful outcomes of TIF.
A global assessment of all outcome measures was performed for each patient to determine the effectiveness of TIF in treating GERD. 24 Patients were considered "in remission" if they had no typical and atypical symptoms, used no PPIs, and were satisfied with their health condition, or "improved" if they had fewer typical or atypical symptoms, required no or only occasional PPIs, and were satisfied. Patients categorized as having ongoing GERD showed no alleviation of their typical or atypical symptoms, required daily or occasional PPIs, and were dissatisfied.
At each site, data were collected using paper-based case report forms and then entered into Excel spreadsheets. All data entered were monitored for accuracy and completeness against the source documents in patient charts (LHHS) or electronic medical record system (MRMC). Data from both sites were aggregated and analyzed using Minitab statistical software (Minitab, Inc, College Station, PA). Continuous variables were summarized as means and standard deviations or medians and ranges. Categorical variables were summarized as counts and percentages. P values for changes at the follow-up compared with those at baseline on PPIs were calculated using the Mann-Whitney U test and paired t test. Fisher's exact test was used to compare frequencies. Values with P < .05 were considered significant. Predictors of clinical effectiveness were evaluated through Pearson's correlation coefficient (r) among demographic, symptomatic and anatomic variables.
Results
From the 124 patients treated, 110 (89%) were available for the follow-up and 81 (74%) were female (Table 1) . Median age was 60 (range 21-87) years. BMI ranged from 19.0 to 47.9, and 16% of the patients were morbidly obese. All patients had chronic GERD for a median 9 (range 1-35) years and were on daily double-dose of PPIs for a median 8 (range 1-25) years. Most patients (97%) reported ineffective symptom control while on medical therapy. In addition, 15% of the patients used daily H2RA, and 32% used daily antacids (mainly Tums).
Review of endoscopic reports confirmed that all patients had moderate anatomic deterioration of the gastroesophageal junction (81% Hill grade II, 19% grade III), and 64% had a small hiatal hernia of 2 or 3 cm (Table 2) . Erosive esophagitis was present in 58% of patients, and 4% had short segment Barrett's esophagus. All 123 procedures were completed successfully and only 1 procedure could not be finished due to hematoma secondary to longtime use of anticoagulants (coumadin and aspirin). The particular patient discontinued aspirin for only 3 days before the procedure instead of the recommended 7 days. Following the aborted surgery, this patient had a normal blood count and chemistry. Chest x ray showed no pulmonary diseases. EKG showed sinus bradycardia, abnormal T wave, but no changes on serial tracings. The patient tolerated the procedure well, did well postoperatively, and was discharged the following day. There were no other perioperative or immediate postoperative complications in the remaining 123 cases.
Median operating time was 45 (range 21-122) minutes, which often included preoperative endoscopy (MRMC). Based on postoperative EGD, TIF resulted in reducing all present hiatal hernia (n = 70) and creating full-thickness esophago-gastric wraps of 300° (range 240° to 340°) around the esophagus, tight adherence to the scope, and median length of 4 (range 3-5) cm above the Z-line.
Symptoms experienced within the first 2 weeks were mild and consisted of epigastric pain (50% of patients), left shoulder pain (15%), sore throat (4%), and nausea (1%). None of the patients complained of postoperative or chronic dysphagia or odynophagia. One patient was hospitalized 1 month after TIF for pneumonia unrelated to the procedure.
Patients experiencing reoccurrence of symptoms after the procedure underwent a complete EGD evaluation. Symptom return in 7 (5.6%) patients at LHHS was related to other gastroesophageal conditions such as diverticulitis (n = 3), colon obstruction (n = 2), or gallbladder stones requiring cholecystectomy (n = 2). Once the conditions were treated, symptoms disappeared. At MRMC, 5 (4.0%) patients experienced early return of symptoms and underwent laparoscopic Nissen revision within 1 to 2 months after TIF. TIF valves in 3 out of these 5 patients were 75% to 85% intact and could have been repaired through TIF revision and placement of additional fasteners. The valves in the remaining 2 patients were disrupted due to retching and severe cough.
There were 14 patients who were lost to follow-up: 6 (4.8%) were unreachable despite several attempts, 5 (4.0%) underwent Nissen revision, 2 (1.6%) had dementia that progressed within 1 year following TIF to the point that they were judged not capable of accurately interpreting the questionnaires by their family members with power of attorney, and 1 (1%) with a partially completed procedure due to intraoperative hematoma.
Follow-up assessment was completed for 110 out of the 123 (89%) successfully treated patients at median 7 (range 5-17) months. Median BMI was 26.5 (range 19.8-47.9) and neither differ significantly from that at baseline (P = .168) nor correlated significantly with any symptomatic outcomes (P > .05). All median symptom scores were significantly reduced (improved) and were within normal ranges at follow-up ( Figure 2 ). Median GERD-HRQL scores were significantly reduced from 28 (range 0-45) pre-TIF on PPIs to 2 (range 0-35) at follow-up (P < .001) and normalized in 80% of the patients. GERSS scores were significantly reduced from 46 (range 8-60) pre-TIF on PPIs to 0 (range 0-12) post-TIF off PPIs (P < .001) and normalized in 79% of the patients. Significantly fewer 
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Pre-TIF Post-TIF patients complained about troublesome heartburn (92% vs 19%, P < .001), regurgitation (85% vs 12%, P < .001), abdominal distension (76% vs 22%, P < .001), dysphagia (68% vs 15%, P < .001), and coughing (77% vs 25%, P < .001) after TIF. Median RSI scores were significantly reduced from 29 (range 3-45) pre-TIF on PPIs to 4 (range 0-30) post-TIF off PPIs (P < .001) and normalized in 75% of the patients. Incidence of troublesome atypical symptoms was significantly reduced from 53% to 5% for hoarseness, from 82% to 15% for clearing throat, from 75% to 15% for excess throat mucus or postnasal drip, from 70% to 15% for troublesome and annoying cough, and from 77% to 12% for globus sensation (P < .001 in all cases). Satisfaction with current health condition after TIF was evaluated as satisfactory by 83%, unsatisfactory by 3% or neither by 7% of patients compared to 3%, and 90% and 7% of patients before TIF on PPIs, respectively. Postoperative use of PPIs was reported by 8 patients as either daily (n = 4, 4%) or occasional (n = 4, 4%) and was completely discontinued by the remaining 102 (93%) patients. The daily use of H2RAs was reported by 3 (3%) patients, and 34 used antacids (mainly Tums) either daily (n = 27, 25%) or occasionally (n = 7, 6%).
EGD with biopsy was performed at a median 7 (range 2-14) months in 53 selected patients (25 out of 60 [42%] at LHHS and 28 out of 50 [56%] at MRMC) who either had esophagitis or hiatal hernia before TIF or experienced symptom return. Among 53 TIF valves examined 47 (89%) were tight with Hill grade I (see Figure 3 for examples of valves at 12 months), 5 (9%) were moderately tight with Hill grade II, and 1 (2%) was loose with Hill grade III. Hiatal hernia present in 34 of the examined patients before TIF remained completely reduced in 33 (97%), and esophagitis present in 30 was healed in 25 (83%) and reduced in 1 (3%). There was 1 new case of hiatal hernia and 1 of esophagitis at the follow-up. Short segment Barrett's esophagus present in 4 patients and esophageal stricture present in 13 before TIF were healed in all examined cases, and gastritis was reduced in 50% (11/22) .
There was a significant positive correlation between Hill grade at follow-up and RSI (r = .493, P = .032) and GERSS (r = .380, P = .011) scores indicating fewer atypical symptoms in patients with tighter Hill grade I valves. Based on the global assessment, 79 (72%) of the patients were considered in "remission" as they were satisfied, had no symptoms, and did not require any medication; and only 9 (8%) patients had ongoing disease (Figure 4 ).
Discussion
Our study population primarily comprised patients more than 60 years old with long-standing chronic GERD treated with high-dose PPIs for more than 5 years. The high prevalence of hiatal hernia and reflux-related complications such as esophagitis, gastritis, and esophageal stricture in our patients was indicative of the advanced stage of their disease. 39 The high frequency of refluxrelated complications and the presence of typical and atypical symptoms poorly controlled on medication are very common in elderly patients and represent a clinical dilemma. 40 Although laparoscopic antireflux surgery results in good clinical outcomes in more than 86% to 92% of elderly patients, 40, 41 the fear of morbidity and mortality associated with surgical treatment in this group of patients often leads to denied or delayed referral of those patients for surgery. 40, 42 The lack of complications, the significant improvement in all symptom scores, and overall satisfaction with health condition exceeding 80% in our study suggest that TIF surgery in this population is a safe, well-tolerated, and effective alternative to laparoscopic surgery for treatment of medically refractory GERD symptoms. Based on our experience we recommend that the use of the current TIF technique is limited to patients with less severe anatomic defects including ≤2 hiatal hernias with transverse dimension not exceeding 3 cm, whereas traditional surgery should be reserved for severe anatomic defects with larger hiatal hernias.
The 123 TIF procedures performed following the standardized TIF2 protocol were shown to be safe and effective. The technique was successful in reducing all hiatal hernia present in 70 patients to <1 cm and creating esophago-gastric wraps extending 300° around the esophagus and up to 5 cm above the Z-line. Our patients experienced no morbidity or mortality associated with TIF. The 1 case of hematoma, which caused the surgery to be aborted prior to completion, was the only intraoperative complication in our study. We believe that that event could likely have been prevented if anticoagulant had been discontinued for the recommended 7 days. This patient had no postoperative complications and was off PPIs and very happy with results at 1 year. Postoperative sequelae commonly associated with laparoscopic antireflux surgery such as gas bloat, dysphasia, and flatulence were almost nonexistent following TIF. The absence of complications and a low reoperation rate of 4.0% were below the published values for laparoscopic fundoplication, 18, 43 as well as for TIF1, 24, 27, 28 suggesting the improved safety profile of TIF2.
A complete discontinuation of PPIs, high rate of symptom relief, and return to normal scores was reported by more than 75% of the patients. Our TIF2 technique resulted in higher clinical effectiveness than that reported by tertiary centers participating in clinical studies with gastro-gastric TIF1 technique. 24, 27, 28 We attributed the apparent clinical superiority of our outcomes to the technical and functional superiority of esophago-gastric fundoplication created with TIF2 and our much higher case volume that exceeded the learning curve reported in the tertiary center studies. Indeed, the functional superiority of esophago-gastric TIF2 has been supported by another US study that reported 61% normalization of acid exposure at 6 months 29 compared with 41% with gastro-gastric TIF1. 24 In our clinical practice, treatment-induced symptom resolution was associated with a significant improvement in the patients' quality of life as reflected in high patient satisfaction. In clinical trials, as well as in clinical practice, the improvement in symptoms indicates an improvement in the manifestation of GERD. Less than 10% of our patients had persistent heartburn requiring medical therapy. This level compares favorably to 32% reported in a community-based study with laparoscopic Nissen. 21 The clinical outcomes of TIF were similar in both of our community hospitals. Patients treated at the small critical access hospital in Kentucky and the large community hospital in Florida were treated following the same protocol and followed up in a standard postoperative fashion. Most of them (83%) were satisfied with their health condition after TIF surgery. Among the satisfied patients there were those who were either happy or very happy with the results and a few who felt they had a life changing experience. The most dramatic effect of TIF was reported in patients who experienced resolution of extra esophageal manifestations of reflux, such as cough, sleeplessness, hoarseness, or sore throat. There were several other unusual manifestations that resolved such as urinary stress incontinence and back pain from chronic cough.
Persistent troublesome chronic cough was present in more than 70% of our patients before TIF. Gastroesophageal reflux disease has been identified as one of the most common causes of chronic cough. 44, 45 Chronic cough accounts for 3.5% of outpatient physician visits and is the most common complaint for which medical attention is sought in the United States. 44, 46 It has also been found to be difficult to treat. In our study 80% of the TIF patients with cough experienced cough elimination based on the normalized RSI scores.
Although our results support clinical efficacy of TIF with respect to symptom and medication elimination, we feel that our study had several limitations. We acknowledge that our symptom data at baseline were based on retrospective recall. The lack of pH measuring systems at our institutions prevented us from measuring esophageal acid exposure before and after TIF. In the absence of sophisticated testing tools, we relied on a detailed history, physical signs, symptom evaluation, barium swallow, and repeated EGD with biopsy to make a diagnosis. This continues to be the most commonly used method of diagnosing GERD among community physicians.
Despite these several limitations, the current study also has several important strengths. It is the largest study to examine the outcomes of TIF2 in the general population. The fact that the study was conducted in the general population means that the findings can more likely be generalized and applied to patients with similar demographic characteristics encountered in community practice or primary care. Our study included all patients treated so there was no bias in the selection of patients for surgery and the follow-up, and therefore, it provides a fair measure of what happens in routine clinical practice. We are confident that our assessment of typical and atypical symptoms was valid and the recall time for symptoms was within the acceptable range to efficiently and accurately capture the frequency and intensity of symptoms. 47 In conclusion, the results of the study support the safety of TIF, demonstrate its efficacy in alleviating typical and atypical GERD symptoms, denote high patient satisfaction, and encourage application of TIF as a surgical alternative for the treatment of chronic GERD patients with troublesome symptoms refractory to PPIs in community settings.
